在KRASG12D驱动的肺腺癌中,SOS1对于瘤发育和微环境调节的关键要求是G12D
Fernando C Baltanás1,2, Rósula García-Navas3, Pablo Rodríguez-Ramos3
1Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain. fcalvo@us.es.
向SOS1显著改善KRAS驱动的G12D肺腺癌 (LUAD) 的存活率,通过减少瘤负担和改变瘤微环境 (TME). 这凸显了SOS1作为LUAD的关键治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- KRAS突变是肺腺癌 (LUAD) 的常见驱动因素.
- SOS蛋白 (SOS1和SOS2) 是RAS蛋白的关氨酸核酸交换因子 (GEF).
- 针对KRAS驱动的途径对于LUAD治疗至关重要.
研究的目的:
- 调查SOS1和SOS2的基因切除对KRASG12D驱动LUAD的影响.
- 评估SOS1作为LUAD中的潜在治疗点.
主要方法:
- KRASG12D驱动的肺腺癌的小鼠模型.
- SOS1或SOS2的遗传切除.
- 分析瘤负担,瘤微环境 (TME) 组件 (纤维细胞,巨细胞,T淋巴细胞).
- 在体内进行瘤细胞注射实验.
- 在人类LUAD数据库的in silico分析.
主要成果:
- 在早期阶段,SOS2除提供了有限的保护.
- 在KRASG12D小鼠中,SOS1切除显著增加了生存率和寿命.
- 通过SOS1切除,减少了瘤负担,改变了TME的组成.
- 索斯1切除诱导了已建立的LUAD瘤的收缩和回归.
- 在 silico 数据支持SOS1在LUAD患者生存中的作用.
结论:
- 对于KRASG12D驱动的LUAD的发展,SOS1是至关重要的.
- 在LUAD中,SOS1除显示出显著的治疗潜力.
- SOS1是KRAS突变LUAD的验证可操作的治疗标.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:39The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
相关概念视频
The Tumor Microenvironment
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
